|
Volumn 2, Issue 7, 2006, Pages 344-345
|
Will arthritis gene therapy become a clinical reality?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADENOVIRUS VECTOR;
ANALGESIC AGENT;
BIOLOGICAL PRODUCT;
COMPLEMENTARY DNA;
ETANERCEPT;
GENDICINE;
HYALURONIC ACID;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
LENTIVIRUS VECTOR;
NONSTEROID ANTIINFLAMMATORY AGENT;
NUTRACEUTICAL;
PARVOVIRUS VECTOR;
RETROVIRUS VECTOR;
ALLOGENEIC STEM CELL TRANSPLANTATION;
CHINA;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DRUG COST;
DRUG MARKETING;
ECONOMIC EVALUATION;
GENE DELIVERY SYSTEM;
GENE THERAPY;
GENE TRANSFER;
GERMANY;
HERPES SIMPLEX VIRUS;
HUMAN;
JOINT PROSTHESIS;
MALIGNANT NEOPLASTIC DISEASE;
NONHUMAN;
NONVIRAL GENE DELIVERY SYSTEM;
OSTEOARTHRITIS;
PRIORITY JOURNAL;
REVIEW;
RHEUMATIC DISEASE;
RHEUMATOID ARTHRITIS;
TRANSGENE;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
VIRAL GENE DELIVERY SYSTEM;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS;
GENE THERAPY;
HUMANS;
|
EID: 33745751677
PISSN: 17458382
EISSN: 17458390
Source Type: Journal
DOI: 10.1038/ncprheum0215 Document Type: Review |
Times cited : (10)
|
References (10)
|